Biotech Values

[DewDiligence]

MON:

…with a target of $65, have you changed your mind?

Not at all—I still think MON is probably the best individual stock to exploit The Global Demographic Tailwind, which is IMO the premiere investing theme in the world today.

Morgan Joseph’s price target is not meant to be taken seriously insofar as the report I posted was about as bullish as any MON report could possibly be. The analyst lowered the price target because the share price has declined and the old target ($90) might now strike some readers as silly.